长期应用非那雄胺治疗良性前列腺增生临床疗效分析

Clinical effects of long-term use of finasteride in treatment of patients with benign prostatic hyperplasia

目的探讨长期应用非那雄胺治疗良性前列腺增生（BPH）的临床疗效及安全性。方法观察患有BPH并坚持服用非那雄胺5mg／d治疗7年以上的患者并分析其临床资料。结果患者治疗前后前列腺体积分别为（48．0±12．5）ml和（41．0±8．4）ml，治疗后前列腺体积明显缩小（t=2．04，P〈0．05）。血清前列腺特异抗原（PSA）治疗前后分别为（3．8±1．5）ug／I。和（1．5±1．1）μg／L，差异有统计学意义（t=5．30，P〈o．05），治疗后2倍PSA值为（2．9±2．2）μg／L，较治疗前差异无统计学意义（t=1．38，P〉0．05）。国际前列腺症状评分（IPSS）治疗后有显著改善[（21．1±7．0）分与（17．1±4．5）分，t=2．09，P〈0．05]。治疗期间1例患者发生急性尿潴留，1例患者出现肉眼血尿，未见其他不良反应。结论长期应用非那雄胺治疗良性BPH疗效好，不良反应小，值得临床推广。

Objective To evaluate the clinical efficacy and safety of long term use of finasteride in the treatment of patients with benign prostatic hyperplasia（BPH）. Methods The clinical data of patients with BPH receiving finasteride 5 mg daily for more than 7 years were analyzed. Results The prostate volumes were significantly reduced from （48.0± 12.5）ml before treatment to （41.0± 8.4）ml after treatment （t=2.04, P〈0. 05）. The serum levels of prostatic specific antigen （PSA） were （3.8±1.5）μg/L and （1.5±1.1） μg/L before and after treatment, respectively（t=5.30,P〈 0.05）, but 2 times in PSA post-treatment were （2.9 ± 2.2） μg/L with no difference versus pretreatment （t =1.38, P〉 0.05）.International prostate symptome score （IPSS） after treatment （17.1 ±4.5） was significantly improved as compared with pre treatment （21.1 ±7.0） （t=2.09, P〈 0.05）. 1 case with acute urinary retention and 1 case with hematuria occurred and no other side effects were found during treatment. Conclusions Long-term use of finasteride for the treatment of BPH is effective, safe and worthy of wide use.